Table 4 |
|||
|
Baseline and day 1 values for protein S, antithrombin III, and IL-6 by treatment group in the PROWESS trial |
|||
|
Parameter |
Treatment group |
||
|
|
|||
|
Placebo (n = 709) |
Drotrecogin alfa (activated) (n = 743) |
P value |
|
|
|
|||
|
Protein S activity |
|||
|
Baseline |
39% (24, 59) |
35% (22, 57) |
0.09 |
|
Day 1 |
36% (23, 57) |
35% (22, 56) |
0.41 |
|
Day 1 change |
0% (-9, 7) |
0% (-10, 9) |
0.59 |
|
Antithrombin III |
|||
|
Baseline |
60% (45, 75) |
59% (44, 75) |
0.50 |
|
Day 1 |
59% (45, 75) |
59% (44, 76) |
0.61 |
|
Day 1 change |
0% (-10, 9) |
0% (-8, 7) |
0.88 |
|
IL-6 |
|||
|
Baseline |
436 (126, 2338) |
523 (156, 2701) |
0.08 |
|
Day 1 |
199 (68, 717) |
211 (77, 685) |
0.44 |
|
Day 1 change |
-157 (-1073, -6) |
-225 (-1922, -27) |
0.006 |
|
|
|||
|
Summary statistics reported as the median (25th percentile, 75th percentile), and P values from Wilcoxon rank-sum tests (P < 0.05 significant). |
|||
|
Shorr et al. Critical Care 2006 10:R92 doi:10.1186/cc4946 |
|||
